Pharmacological properties of TV3326, a cholinesterase and brain selective monoamine oxidase inhibitor for the treatment of dementia co-morbid with depression

Although TV3326 had less than one-40th of the AChE inhibitory activity of rivastigmine in vitro, it showed only one-seventh of the inhibitory activity of rivastigmine on rat brain AChE after oral administration.10 The rate of onset of brain AChE inhibition by TV3326 was significantly slower than that of rivastigmine, and of longer duration.10 This should result in a lower incidence of nausea and vomiting than is encountered with rivastigmine and may obviate the necessity for twice daily dosing.